Purdue Pharma has named Julie Ducharme as its CSO. Ducharme rejoins Purdue at a time when it is trying to expand beyond the opioids that built but now threaten to sink its business.
At its peak, Purdue pulled in more than $3 billion a year and employed close to 2,000 people. Those days are now behind Purdue, with the Wall Street Journal reporting sales will fall below $1 billion this year for the first time in a decade. The situation could get worse. Facing around 2,000 lawsuits over its alleged role in the opioid crisis, there are reports that Purdue will file for bankruptcy.
To recover, Purdue needs to move beyond OxyContin. The appointment of Ducharme as VP and CSO is part of that effort.
Ducharme spent the past two years as managing director for R&D at Mundipharma. Before a recent revision to its website, Purdue listed Mundipharma as an “independent associated” company that helped extend its reach into more than 30 countries. The Sackler family that owns Purdue reportedly controls Mundipharma through trusts.
During Ducharme’s time at Mundipharma, the company supported Purdue’s R&D efforts, for example by advancing four drug candidates against 14 types of cancer. The oncology pipeline is spearheaded by tinostamustine, an alkylating deacetylase inhibitor that came through a phase 1 trial last year.
Before joining Mundipharma, Ducharme spent a little over a year serving as Purdue’s VP of R&D. Earlier in her career, Ducharme worked at AstraZeneca for 15 years before doing a three-year stint as general manager, human health therapeutics at National Research Council Canada.
In commenting on her decision to rejoin Purdue, Ducharme highlighted the work the company is doing on drugs against cancer indications and CNS conditions such as ADHD, plus its efforts to develop non-opioid treatments for pain. Ducharme said Purdue’s “obvious compassion for patients” and “numerous efforts to help communities address the public health crisis” attracted her to the company.
By Nick Paul Taylor
Source: Fierce Biotech
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
